Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Spurned By NICE On Avastin In Bowel Cancer, Roche Looks To U.K. Cancer Drugs Fund

This article was originally published in The Pink Sheet Daily

Executive Summary

NICE's definitive decision against Avastin in bowel cancer forces Roche to turn to Cancer Drugs Fund.

You may also be interested in...

NICE Rejects Avastin For Ovarian Cancer On Cost, Okays Lucentis

NICE has knocked back Avastin for ovarian cancer due to high cost, but Roche may have a plausible market strategy in place for the drug in the UK.

Avastin's Next Stop May Be Hearing As FDA Starts Withdrawal Process For Breast Cancer Claim

Agency officials stress that FDA is eager to work with Genentech on future studies to identify a subpopulation of responders.

Avastin's Stumble Again At NICE Underscores Importance Of Overall Survival Data

NICE rejection of Roche's Avastin comes a week ahead of target dates for U.S. and EU decisions on possibly withdrawing the indication, but still offers instructive lessons for working with technology assessment groups.

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts